Morgan Stanley analyst Sean Laaman raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $26 from $25 and keeps an Equal Weight rating on the shares. Acadia achieved “solid FY25 performance” and still guides above the Street view for Nuplazid, but in line for Daybue, the analyst tells investors in a post-earnings note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target lowered to $24 from $25 at Stifel
- Acadia Pharmaceuticals price target raised to $35 from $34 at Citizens
- Balancing Daybue Momentum and Nuplazid Uncertainty: Justifying a Neutral Stance on ACADIA
- ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating
- Balancing Robust Nuplazid Outlook and RADIANT Trial Uncertainty: Rationale for Maintaining a Hold on Acadia